Back to Journals » Clinical Ophthalmology » Volume 11

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment

Authors Mizoguchi T, Ozaki M, Ogino N

Received 7 May 2017

Accepted for publication 18 July 2017

Published 27 September 2017 Volume 2017:11 Pages 1747—1753

DOI https://doi.org/10.2147/OPTH.S141279

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Takanori Mizoguchi,1 Mineo Ozaki,2 Nobuchika Ogino3

1Mizoguchi Eye Clinic, Ophthalmology, Sasebo, Japan; 2Ozaki Eye Hospital, Ophthalmology, Miyazaki, Japan; 3Nishigaki Eye Clinic, Ophthalmology, Nagoya, Japan

Purpose: To evaluate the efficacy and safety of 0.05% epinastine and 0.1% olopatadine eye drop preparations as seasonal and preseasonal treatments in patients with seasonal allergic conjunctivitis (SAC).
Subjects and methods:
This was a prospective, randomized, case-control study involving two institutions. The subjects were patients diagnosed with SAC at two institutions between February and March in 2014. To examine the clinical effects of seasonal treatment, 0.05% epinastine and 0.1% olopatadine were administered, and their effects were investigated every 2 weeks (Stage 1). To evaluate the clinical effects of preseasonal therapy, in January 2015, the same eye drop preparations as adopted in Stage 1 were administered to patients who had participated in Stage 1 and provided consent to participate in this study, and their effects were investigated every month (Stage 2).
Results: In Stage 1, the 0.05% epinastine group consisted of 43 patients, and the 0.1% olopatadine group consisted of 42 patients. There were significant improvements in the total symptom and objective finding scores at each time point after administration in comparison with those before its baseline, but there were no significant differences between the two groups. In Stage 2, the 0.05% epinastine group consisted of 15 patients, and the 0.1% olopatadine group consisted of 14 patients. The rate of change in the total symptom score in comparison with that at the baseline of preseasonal treatment was significantly higher in the 0.1% olopatadine group 1 month after the start of treatment, suggesting symptom deterioration (P=0.025). There was no significant difference in the rate of change in the total objective finding score between the two groups.
Conclusion: Seasonal treatment with 0.05% epinastine or 0.1% olopatadine was equally effective for patients with allergic conjunctivitis. However, for preseasonal therapy, 0.05% epinastine was more effective than 0.1% olopatadine.

Keywords: 0.05% epinastine, 0.1% olopatadine, seasonal allergic conjunctivitis, preseasonal treatment, seasonal treatment, inverse agonist

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Clinical results of Trabectome surgery for open-angle glaucoma

Mizoguchi T, Nishigaki S, Sato T, Wakiyama H, Ogino N

Clinical Ophthalmology 2015, 9:1889-1894

Published Date: 9 October 2015

Plateau iris in Japanese patients with primary angle closure and primary angle closure glaucoma

Mizoguchi T, Ozaki M, Wakiyama H, Ogino N

Clinical Ophthalmology 2015, 9:1159-1163

Published Date: 29 June 2015

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1579-1584

Published Date: 25 September 2012